Home> Products> sulfonylureas

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-09-25T10:46:50.098Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b8014256f7114dfbd884", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.", "price": 3.0, "discountamount": 1.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medical advice", "generally safe", "healthcare provider", "food preferably", "extended halflife", "crucial role", "dpp4 enzyme", "sulfonylureas mechanism", "antidiabetic medications", "low risk", "vital role", "sustainable option", "regular exercise", "healthy diet", "effective approach", "support adults", "trelaqwk 100trelaqwk 100", "hormones play", "natural hormones", "dose seek guidance", "promote insulin release", "degrades incretin hormones", "experience unusual symptoms", "skin irritation seek", "onceaweek administration setting", "improved glycemic control", "regulating blood sugar", "weight gain carries", "suppress glucagon playing", "improving glycemic control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2132, "imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:42:25.371Z", "updatedon": "2025-06-11T11:17:09.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Trelagliptin 100mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin side effects", "Trelagliptin brand name", "Trelagliptin brands in India", "Trelagliptin uses", "Trelagliptin 100mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b74dc10e9000933fa1d7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern, once-a-week oral antidiabetic medication containing Trelagliptin 50mg, developed to support adults with type 2 diabetes mellitus (T2DM). This formulation is designed to improve blood glucose regulation while offering patients the convenience of weekly dosing. Created under rigorous quality standards, TRELAQWK 50 combines therapeutic effectiveness with enhanced compliance and lifestyle ease.\n\nActive Ingredient:\nTrelagliptin 50mg\nA next-generation DPP-4 (Dipeptidyl Peptidase-4) inhibitor with an extended half-life, enabling once-weekly administration. It helps improve glycemic control by preserving incretin hormones that naturally support insulin secretion and reduce glucagon production.\n\nKey Advantages:\nDelivers long-lasting blood sugar control with just one tablet per week\n\nEnhances insulin production and decreases glucagon levels in a glucose-dependent manner\n\nEffectively lowers both fasting and post-meal blood sugar levels\n\nPerfect for patients who find daily medications challenging\n\nLowers the risk of hypoglycemia when not combined with insulin or sulfonylureas\n\nContributes to better HbA1c levels over continued use\n\nMechanism of Action:\nTRELAQWK 50 functions by inhibiting the DPP-4 enzyme, which degrades incretin hormones like GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide). By preventing their breakdown, Trelagliptin extends the action of these hormones, resulting in increased insulin release and reduced glucagon levels. This mechanism is particularly effective after meals, helping maintain optimal blood glucose levels throughout the week.\n\nUsage Instructions:\nTake one tablet weekly, ideally on the same day each week\n\nCan be taken with or without meals\n\nSwallow whole with water—do not crush or chew\n\nFollow your doctor's dosing guidelines exactly\n\nIf you miss a dose, do not take two tablets together; speak with your doctor for guidance\n\nPossible Side Effects:\nTRELAQWK 50 is usually well-tolerated. However, some individuals may notice:\n\nHeadache\n\nCommon cold-like symptoms (nasopharyngitis)\n\nMild diarrhea\n\nGastrointestinal discomfort\n\nRare allergic responses like skin rashes or itching\n\nShould any side effects persist or worsen, consult your healthcare provider immediately.", "price": 375.0, "discountamount": 112.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "offering patients", "worsen consult", "skin rashes", "chew follow", "meals swallow", "dpp4 enzyme", "sulfonylureas contributes", "enhanced compliance", "support adults", "trelaqwk 50trelaqwk 50", "hormones resulting", "hba1c levels", "tablet weekly ideally", "week usage instructions", "increased insulin release", "reduced glucagon levels", "degrades incretin hormones", "decreases glucagon levels", "preserving incretin hormones", "healthcare provider immediately", "side effects persist", "doctors dosing guidelines", "breakdown trelagliptin extends", "glp1 glucagonlike peptide1", "weekly dosing created" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2131, "imageuri": "https://productimages.withfloats.com/actual/6842b764900dc96c430f8095.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b764900dc96c430f8095.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:39:25.819Z", "updatedon": "2025-08-28T11:15:31.153Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2131", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin in India", "Trelagliptin brand name", "trelagliptin 50 mg", "trelagliptin 50mg", "trelagliptin 50mg", "trelagliptin 50mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68134d097702eb2332e5ccb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 40", "description": "GLICLAGLAZE 40 is an oral antidiabetic medication containing Gliclazide 40 mg, formulated to effectively manage Type 2 Diabetes Mellitus. It belongs to the class of drugs known as sulfonylureas, which are specifically designed to control blood glucose levels in adults who cannot manage diabetes through diet and exercise alone. By promoting insulin secretion and improving glycemic control, GLICLAGLAZE 40 helps prevent long-term complications associated with uncontrolled diabetes, such as nerve damage, kidney issues, and cardiovascular diseases.\n\nKey Ingredient\nGliclazide (40 mg):\nGliclazide is a second-generation sulfonylurea, known for its dual effect: stimulating insulin release from the pancreas and offering antioxidant properties. It not only lowers blood sugar but also provides vascular protection, making it suitable for patients at risk of cardiovascular events.\n\nKey Benefits\nEffectively reduces high blood sugar levels in Type 2 diabetes\n\nStimulates natural insulin secretion from pancreatic beta cells\n\nProvides cardiovascular protection by improving endothelial function\n\nMinimizes the risk of microvascular complications like retinopathy and nephropathy\n\nSuitable for long-term glycemic control when lifestyle measures are insufficient\n\nHelps maintain a stable glucose profile throughout the day\n\nHow Does It Work?\nGLICLAGLAZE 40 works by targeting the pancreas to enhance the secretion of insulin, which is essential for lowering blood glucose levels. Gliclazide binds to specific receptors on pancreatic beta cells, triggering the release of insulin in a glucose-dependent manner. This ensures that the medication works primarily when glucose levels are elevated, thus reducing the risk of hypoglycemia compared to older sulfonylureas. Additionally, its antioxidant properties contribute to improved vascular health, protecting blood vessels from oxidative damage often seen in diabetic patients.\n\nDirections for Use\nTake GLICLAGLAZE 40 exactly as prescribed by your healthcare provider\n\nUsually taken once or twice daily, preferably before meals\n\nSwallow the tablet whole with water — do not crush or chew\n\nMaintain a regular schedule for meals and medication to avoid hypoglycemia\n\nMonitor blood glucose levels regularly to track progress\n\nAlways combine with a balanced diet and exercise plan for optimal results\n\nSide Effects\nThough generally well-tolerated, GLICLAGLAZE 40 may cause some side effects:\n\nCommon Side Effects:\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness or light-headedness\n\nNausea or stomach discomfort\n\nWeight gain (in some patients)\n\nRare but Serious Side Effects:\n\nLiver enzyme abnormalities\n\nSkin rash or allergic reaction\n\nBlood disorders like anemia or thrombocytopenia\n\nVisual disturbances (usually temporary)\n\nSeek immediate medical attention if symptoms of severe hypoglycemia, such as confusion, fainting, or seizures, occur.", "price": 120.0, "discountamount": 34.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "gliclaglaze 40", "exercise plan", "balanced diet", "meals swallow", "nephropathy suitable", "gliclaglaze 40gliclaglaze 40", "seizures occur", "confusion fainting", "severe hypoglycemia", "medical attention", "temporary seek", "patients rare", "lightheadedness nausea", "track progress", "regular schedule", "daily preferably", "healthcare provider", "oxidative damage", "hypoglycemia compared", "glucosedependent manner", "specific receptors", "lifestyle measures", "microvascular complications", "secondgeneration sulfonylurea", "uncontrolled diabetes", "manage diabetes", "specifically designed", "chew maintain", "glucose levels", "cardiovascular protection", "promoting insulin secretion", "diabetic patients directions", "older sulfonylureas additionally", "medication works primarily", "oral antidiabetic medication", "stable glucose profile", "insufficient helps maintain", "vascular protection making", "thrombocytopenia visual disturbances", "antioxidant properties contribute", "longterm glycemic control", "pancreatic beta cells", "lowers blood sugar", "offering antioxidant properties" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2099, "imageuri": "https://productimages.withfloats.com/actual/68134d0b4b698d44a8c316f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/68134d0b4b698d44a8c316f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-01T10:29:29.141Z", "updatedon": "2025-05-01T10:29:29.141Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-40/2099", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Gliclazide 40 mg", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 40 mg uses in Hindi", "Gliclazide 40mg brands", "Gliclazide 40 mg price", "Gliclazide 40mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67e151dde76674b1ca044d32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 25 mg and Sitagliptin 100 mg", "description": "GLIEMPAFLOZIN SITA 25/100 is an advanced anti-diabetic medication containing Empagliflozin 25 mg and Sitagliptin 100 mg, formulated to effectively control blood sugar levels in individuals with Type 2 Diabetes Mellitus. This powerful combination helps regulate glucose levels, improve insulin function, and reduce the risk of diabetes-related complications. It is designed for patients requiring dual therapy to achieve better glycemic control.\n\n \nKey Benefits:\n \nEffective Blood Sugar Control – Lowers HbA1c levels and maintains long-term glycemic stability.\nPromotes Weight Loss – Empagliflozin helps in reducing excess body weight by eliminating excess glucose.\nHeart & Kidney Protection – Reduces the risk of cardiovascular diseases and kidney complications.\nEnhanced Insulin Sensitivity – Improves insulin response and minimizes glucose spikes.\nConvenient Dual Therapy – Combines two powerful anti-diabetic agents in one tablet for better diabetes management.\n\n \nHow Does It Work?\n \n\nEmpagliflozin blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting glucose excretion through urine. This helps lower blood sugar levels naturally while supporting heart and kidney health.\n\nSitagliptin works by inhibiting the DPP-4 enzyme, which increases the levels of incretin hormones that stimulate insulin release and reduce glucose production in the liver.\n\nTogether, they offer comprehensive diabetes control by lowering blood sugar through different mechanisms, making it a superior option for Type 2 Diabetes management.\n\n \nDirections for Use:\n \n\nTake GLIEMPAFLOZIN SITA 25/100 as prescribed by your doctor.\n\nSwallow the tablet whole with water, preferably once daily with or without food.\n\nMaintain a healthy diet and regular exercise for best results.\n\nDo not exceed the recommended dosage without consulting a healthcare professional.\n\n \nSide Effects:\n \n\nWhile generally well-tolerated, some users may experience:\n\nFrequent Urination (due to glucose excretion)\nDehydration & Dizziness\nMild Nausea or Stomach Discomfort\nHypoglycemia (Low Blood Sugar) – Especially if combined with insulin or sulfonylureas\nUrinary or Genital Infections (due to increased sugar excretion in urine)\n\nSeek medical attention if you experience severe allergic reactions, persistent dizziness, or signs of dehydration.", "price": 425.0, "discountamount": 128.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "sulfonylureas urinary", "generally welltolerated", "recommended dosage", "regular exercise", "healthy diet", "food maintain", "water preferably", "doctor swallow", "gliempaflozin sita 25100", "superior option", "mechanisms making", "incretin hormones", "dpp4 enzyme", "supporting heart", "sglt2 protein", "diabetes management", "cardiovascular diseases", "diabetesrelated complications", "empagliflozin 25mg", "reduce glucose production", "stimulate insulin release", "work empagliflozin blocks", "increased sugar excretion", "genital infections due", "lowering blood sugar", "promoting glucose excretion", "powerful antidiabetic agents", "sitagliptin 100mg formulated", "advanced antidiabetic medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2071, "imageuri": "https://productimages.withfloats.com/actual/67e151f4a5330495f6fabda3.png", "tileimageuri": "https://productimages.withfloats.com/tile/67e151f4a5330495f6fabda3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-24T12:36:45.699Z", "updatedon": "2025-03-27T13:02:48.654Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25-mg-and-sitagliptin-100-mg/2071", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN SITA 25/100", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and sitagliptin combination", "Empagliflozin 25 mg substitute", "Empagliflozin 25 mg brands in India", "Empagliflozin 25 mg Price in India", "Empagliflozin brands in India", "Empagliflozin 25 mg", "Empagliflozin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35925da7066e27fe83d3a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 10 mg, Linagliptin5 mg", "description": "GLIEMPAFLOZIN LINA is an advanced oral antidiabetic medication that combines Empagliflozin (10 mg) and Linagliptin (5 mg) to effectively manage Type 2 Diabetes Mellitus (T2DM). This combination helps regulate blood sugar levels while offering cardiovascular and renal benefits. It is a dual-action therapy that enhances insulin secretion and promotes glucose excretion, making it an excellent choice for diabetes control.\n\n \nKey Benefits:\n \n\nEffective Blood Sugar Control: Helps lower and maintain optimal blood glucose levels in patients with Type 2 Diabetes.\nDual Mechanism Action: Targets different pathways to improve insulin response and reduce glucose reabsorption.\nWeight Management Support: May aid in weight loss by eliminating excess glucose from the body.\nHeart and Kidney Protection: Reduces cardiovascular risks and provides potential renal protection for diabetic patients.\nConvenient Dosing: Single-tablet formulation for ease of administration and better patient adherence.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN LINA works through a dual mechanism:\nEmpagliflozin blocks the SGLT2 transporter in the kidneys, preventing glucose reabsorption and increasing its elimination through urine. This helps lower blood sugar levels and reduces the risk of cardiovascular complications.\n\nLinagliptin inhibits DPP-4 enzyme activity, thereby increasing incretin hormone levels. This leads to increased insulin secretion and decreased glucagon production, ensuring better glucose metabolism.\n\n \nDirections for Use:\n \n\nTake one tablet daily or as prescribed by your healthcare provider.\n\nCan be taken with or without food.\n\nMaintain a healthy diet and regular exercise routine for optimal results.\n\nDo not crush, chew, or break the tablet; swallow it whole with water.\n\n \nSide Effects:\n \n\nWhile GLIEMPAFLOZIN LINA is well-tolerated, some individuals may experience:\n\nFrequent urination due to increased glucose excretion.\n\nMild dehydration or increased thirst.\n\nHypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas.\n\nUrinary tract infections (UTIs) or genital yeast infections.\n\nAllergic reactions, such as rash or itching (rare).\n\nDigestive discomfort, including nausea or diarrhea.", "price": 315.0, "discountamount": 95.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "gliempaflozin lina", "tablet swallow", "crush chew", "optimal results", "healthy diet", "food maintain", "healthcare provider", "tablet daily", "sglt2 transporter", "patient adherence", "body heart", "weight loss", "excellent choice", "dualaction therapy", "offering cardiovascular", "linagliptin 5 mg", "renal benefits", "increased insulin secretion", "potential renal protection", "improve insulin response", "enhances insulin secretion", "water side effects", "regular exercise routine", "glucose metabolism directions", "eliminating excess glucose" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2045, "imageuri": "https://productimages.withfloats.com/actual/67a35955c525b12e62733a1a.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35955c525b12e62733a1a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:27:17.266Z", "updatedon": "2025-03-17T11:06:59.346Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-10-mg-linagliptin5-mg/2045", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 10MG/ 5MG ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg", "Empagliflozin/linagliptin side effects", "Linagliptin empagliflozin combination brand name", "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }